187 related articles for article (PubMed ID: 25140894)
1. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
Karamitopoulou E; Thies S; Zlobec I; Ott K; Feith M; Slotta-Huspenina J; Lordick F; Becker K; Langer R
Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
[TBL] [Abstract][Full Text] [Related]
2. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
3. Clinical assessment of tumor regression grade systems in gastroesophageal adenocarcinoma following neoadjuvant chemotherapy.
Lütken C; Sheikh K; Willemoe GL; Achiam MP; Hasselby JP
Pathol Res Pract; 2021 Aug; 224():153538. PubMed ID: 34243107
[TBL] [Abstract][Full Text] [Related]
4. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
Fleischmann A; Thalmann GN; Perren A; Seiler R
Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
[TBL] [Abstract][Full Text] [Related]
5. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
Wu TT; Chirieac LR; Abraham SC; Krasinskas AM; Wang H; Rashid A; Correa AM; Hofstetter WL; Ajani JA; Swisher SG
Am J Surg Pathol; 2007 Jan; 31(1):58-64. PubMed ID: 17197919
[TBL] [Abstract][Full Text] [Related]
6. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
7. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases.
Becker K; Langer R; Reim D; Novotny A; Meyer zum Buschenfelde C; Engel J; Friess H; Hofler H
Ann Surg; 2011 May; 253(5):934-9. PubMed ID: 21490451
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
[TBL] [Abstract][Full Text] [Related]
9. A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapy.
Langer R; Becker K; Zlobec I; Gertler R; Sisic L; Büchler M; Lordick F; Slotta-Huspenina J; Weichert W; Höfler H; Feith M; Ott K
Ann Surg Oncol; 2014 Mar; 21(3):915-21. PubMed ID: 24281419
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas.
Langer R; Ott K; Feith M; Lordick F; Siewert JR; Becker K
Mod Pathol; 2009 Dec; 22(12):1555-63. PubMed ID: 19801967
[TBL] [Abstract][Full Text] [Related]
11. Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas.
Thies S; Guldener L; Slotta-Huspenina J; Zlobec I; Koelzer VH; Lugli A; Kröll D; Seiler CA; Feith M; Langer R
Hum Pathol; 2016 Jun; 52():1-8. PubMed ID: 26980046
[TBL] [Abstract][Full Text] [Related]
12. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
13. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
[TBL] [Abstract][Full Text] [Related]
15. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
[TBL] [Abstract][Full Text] [Related]
16. International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems.
Chetty R; Gill P; Govender D; Bateman A; Chang HJ; Deshpande V; Driman D; Gomez M; Greywoode G; Jaynes E; Lee CS; Locketz M; Rowsell C; Rullier A; Serra S; Shepherd N; Szentgyorgyi E; Vajpeyi R; Wang LM; Bateman A
Hum Pathol; 2012 Nov; 43(11):1917-23. PubMed ID: 22575264
[TBL] [Abstract][Full Text] [Related]
17. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.
Langer R; Becker K
Virchows Arch; 2018 Feb; 472(2):175-186. PubMed ID: 28918544
[TBL] [Abstract][Full Text] [Related]
18. Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes.
Tsekrekos A; Vieth M; Ndegwa N; Bateman A; Flejou JF; Grabsch HI; Mastracci L; Meijer SL; Saragoni L; Sheahan K; Shetye J; Yantiss R; Lundell L; Detlefsen S
Hum Pathol; 2021 Oct; 116():94-101. PubMed ID: 34284051
[TBL] [Abstract][Full Text] [Related]
19. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey.
Saliba G; Detlefsen S; Carneiro F; Conner J; Dorer R; Fléjou JF; Hahn H; Kamaradova K; Mastracci L; Meijer SL; Sabo E; Sheahan K; Riddell R; Wang N; Yantiss RK; Lundell L; Low D; Vieth M; Klevebro F
Hum Pathol; 2021 Feb; 108():60-67. PubMed ID: 33221343
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
